The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. https://allenxbuf521175.onzeblog.com/39206676/glp-3-retatrutide-a-comparative-analysis